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Background: Fever is one of the most common symptoms in children and is the physiological response of the human immune
system to external pathogens. However, effectiveness studies of single and combined antipyretic therapy are relatively few due
to lack of data. In this study, we used large-scale patient-generated health data from mobile apps to compare antipyretic affects
between single and combination antipyretics.
Objective: We aimed to establish combination patterns of antipyretics and compare antipyretic affects between single and
combination antipyretics using large-scale patient-generated health data from mobile apps.
Methods: This study was conducted using medical records of feverish children from July 2015 to June 2017 using the Fever
Coach mobile app. In total, 3,584,748 temperature records and 1,076,002 antipyretic records of 104,337 children were analyzed.
Antipyretic efficacy was measured by the mean difference in the area under the temperature change curve from baseline for 6
hours, 8 hours, 10 hours, and 12 hours after antipyretic administration in children with a body temperature of ≥38.0 ℃ between
single and combination groups.
Results: The single antipyretic and combination groups comprised 152,017 and 54,842 cases, respectively. Acetaminophen
was the most commonly used single agent (60,929/152,017, 40.08%), and acetaminophen plus dexibuprofen was the most common
combination (28,065/54,842, 51.17%). We observed inappropriate use, including triple combination (1205/206,859, 0.58%) and
use under 38 ℃ (11,361/206,859, 5.50%). Combination antipyretic use increased with temperature; 23.82% (33,379/140,160) of
cases were given a combination treatment when 38 ℃ ≤ temperature < 39 ℃, while 41.40% (1517/3664) were given a combination
treatment when 40 ℃ ≤ temperature. The absolute value of the area under the curve at each hour was significantly higher in the
single group than in the combination group; this trend was consistently observed, regardless of the type of antipyretics. In particular,
the delta fever during the first 6 hours between the two groups showed the highest difference. The combination showed the lowest
delta fever among all cases.
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Conclusions: Antipyretics combination patterns were analyzed using large-scale data. Approximately 75% of febrile cases used
single antipyretics, mostly acetaminophen, but combination usage became more frequent as temperature increased. However,
combination antipyretics did not show definite advantages over single antipyretics in defervescence, regardless of the combination.
Single antipyretics are effective in reducing fever and relieving discomfort in febrile children.
(JMIR Mhealth Uhealth 2021;9(5):e21668) doi: 10.2196/21668
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Introduction
Fever is one of the most common symptoms in children and
represents a physiologic response of the human immune system
against external pathogens. In particular, fever is reported to be
the most common cause of children’s emergency room visits,
accounting for 26.4% to 37.4% of visits [1,2]. According to
studies in Korea, most causes of childhood fever are viral
infections such as mild acute upper respiratory infections [1,2].
However, as parents wish to lower their child’s temperature to
within a normal range, antipyretics are commonly administered
[3]. This fever phobia has caused caregivers to treat fever
aggressively with a combination of antipyretics such as
acetaminophen (ACE) and ibuprofen (IBU), often in
combination. Despite the lack of official recommendations,
combination antipyretic therapy with ACE and IBU is
commonly used to treat fever that does not respond to
monotherapy [4].
Pharmacologic evidence suggests that the combination of ACE
and IBU may be well tolerated because both medications have
different metabolic pathways that are not affected by each other
[5]. Both drugs are well tolerated, with wide therapeutic margins
and proper dosing.
However, because each antipyretic has its own adverse effects,
the combination of antipyretics should be properly guided based
on reference data regarding antipyretic efficacy. Adverse effects
caused by ACE and IBU are well known because of their
frequent use worldwide. Hepatic disorders are the most common
adverse drug reaction of ACE, whereas gastrointestinal tract
disorder, kidney injury, hypersensitivity reaction, and, more
recently, noticeable cardiovascular events are frequently reported
adverse effects of nonsteroidal anti-inflammatory drugs
(NSAIDs) such as IBU [6,7]. In addition, drug misdose or
overdose is an important public health issue, especially with
antipyretics because most antipyretics are administered to
children. Misdosing of antipyretics has been reported in
approximately 50% of ACE and 25% of IBU administrations
[8-10]; among these, 8.4% to 14% and 9.6% to 14% of patients
received higher doses, respectively. Infants aged younger than
1 year were more likely to receive an inaccurate dose than older
children because caregivers who used inaccurate doses had
difficulty in dosing based on their children’s weight [11].
Overdose of ACE is one of the leading causes of acute liver
failure in Western countries [10]. In addition, elevated liver
transaminases have been described even at recommended doses
in children as well as adults [12].
Several randomized controlled trials that have incorporated
combination antipyretics have compared the antipyretic effect
and toxicity; these studies favored combination therapy for
achieving and sustaining an afebrile state [5,10,13-15]. However,
the trial limitations included relatively small numbers of patients
and a lack of continuously tracked temperatures, especially in
the home setting where combination therapy was administered.
Thus, concerns regarding whether combination antipyretics
have substantial benefit remain.
To address this concern, drug administration and corresponding
temperature recordings are required in a large cohort. These
data can be obtained through mobile apps where caregivers can
record their child’s data in real time. In this study, we used the
mobile app Fever Coach (Mobile Doctor) to obtain real-world
data to determine the combination antipyretic use pattern and
effects administered at home in numerous febrile children in




To compare the fever reduction effect between single and
combination antipyretics, we used temperature and antipyretic
records from feverish children collected from July 2015 to June
2017 using the Fever Coach app.
We defined the onset of a fever case when the temperature
exceeded 38.0 ℃, and the offset of a fever case when the
temperature fell below 38.0 ℃ [16,17]. Temperature values
were obtained using linear imputation techniques when values
were missing between two neighboring actual temperatures.
We used this linear imputation technique with the assumption
that fever progression would show a linear characteristic
between two short measurements.
The duration was defined as the time elapsed between onset
and offset. Antipyretic efficacy was measured by the mean
difference between the area under the curve (AUC) and the
average temperature changes of the single and combination
groups. Because both the degree of temperature elevation and
the duration of fever affect patients, the AUC (the product of
body temperature and duration) has been used as an indicator
for total fever exposure in children and was the study end point
to determine the effect of drugs including antipyretics [18-20].
The AUC was calculated using the area under the temperature
change curve from baseline for 6 hours, 8 hours, 10 hours, and
12 hours after antipyretic administration in children with a body
temperature of ≥38.0 ℃. The populations of single and
combination groups were then analyzed with two threshold
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temperatures at the time of first antipyretic administration: >38
or 39 ℃. We compared the mean difference of the negative
AUC from onset through 6 hours, 8 hours, 10 hours, and 12
hours and the average temperature changes over time according
to the antipyretic administration pattern.
This study was approved by the institutional review board of
Asan Medical Center (2018-0179). The need for informed
consent was waived by the ethics committee as this study used
routinely collected log data that were anonymously managed
at all stages, including during data cleaning and statistical
analyses. This study was conducted in accordance with the
STROBE statement (Multimedia Appendix 1).
Setting
The app is based on pediatric thermal standards and assesses a
child’s condition based on user input to provide guidelines for
antipyretic use. After registration, the user may enter various
fever-related information including body temperature, other
symptoms, dose and time of antipyretic administration,
vaccination and antibiotic history, and physician-made diagnosis
if the child was seen by a physician for the management of the
current illness. Based on these inputs, the app provides
instructions for fever control and advises on the timing of
seeking medical attention. The service was designed and
reviewed by two board-certified family physicians and one
board-certified pediatrician [21]. The app supports the effective
and accurate control of common fever symptoms and is available
as a free download from Google Play and the App Store. As of
June 31, 2017, 393,700 users had registered their child with the
app.
The items in the dashed boxes show the detailed attributes on
temperature and antipyretic records and the diagnosis of feverish
children (Figure 1). The “Enter the temperature” function
records the temperature, time, and experience of febrile
convolutions. The “Enter the dose” function records the
antipyretic type, ingredients, brand name, doses, and time. The
“Today’s records” function records the date and time of the
hospital visit, diagnosis, and the doctor’s instruction for the
child. The diagnosis includes 21 febrile illnesses that are
common in children and diseases that are directly entered.
Figure 1. Antipyretic and temperature screens in the Fever Coach app: Enter the temperature (left), Enter the dose (center), Enter the diagnosis (right).
The original app was in Korean.
Sample and Sampling
We analyzed the log of all users and their children who signed
up and logged in to the Fever Coach app more than once from
July 2015 to June 2017. Figure 2 shows the target population
selection flow of the study. A total of 5,580,762 body
temperatures and 1,693,295 antipyretic records were collected
on 393,700 children. Among them, we excluded children
weighing <2 kg or >50 kg, children <0 days or >7000 days after
birth, and children without antipyretic or fever records.
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Figure 2. Data collection flow chart. One case refers to a single record for 72 hours after the first antipyretic drug is administered.
Since a child may experience multiple fevers, one case indicated
a single record for 72 hours after the first antipyretic drug was
administered. We obtained 494,929 cases with 4,891,960
temperature records and 1,666,346 antipyretic records.
For 72 hours, cases with only one type of antipyretic were
defined as a single group (152,019 cases with 2,527,133
temperature and 706,317 antipyretic records), and those
including more than one type of antipyretic were recorded as a
combination group (54,842 cases with 1,057,615 temperature
and 369,685 antipyretic records).
Statistical Analysis
We compared the demographic and baseline characteristics of
children between single and combination groups by means and
frequencies using the Student t test and chi-square test,
respectively. We also compared demographic and body
temperature information according to antipyretic administration
patterns in single and combination groups by Student t test and
chi-square test. For the antipyretic effect of single and
combination treatment, the AUC values and the fever reduction
indicators were analyzed by groups using Student t test based
on the temperature at the first antipyretic administration (>38
℃ group, >39 ℃ group). We analyzed the average body
temperature change over time by single versus combination and
each type of antipyretic administration using a line graph. The
effect sizes were calculated using Cohen d coefficient
interpretation [22]. All reported P values were 2-sided, and
P<.05 was considered significant. Data analyses were conducted




From July 2015 to June 2017, 3,584,748 temperature records
and 1,076,002 antipyretic medication records for 104,337
children were analyzed. Among 206,859 fever cases, the single
group comprised 152,017 cases, which encompassed 2,527,133
temperature and 706,317 antipyretic records (Table 1). The
combination group comprised 54,842 cases, which encompassed
1,057,615 temperature and 369,685 antipyretic records. When
antipyretics were used in combination, they were mostly
administered alternatively at 4- to 6-hour intervals (data not
shown). As shown in Table 1, most variables were statistically
different between the single and combination groups, except
the presence of a diagnosis. The proportion of males was slightly
higher in the combination group, but no definite male or female
predominance was found in either group. Children in the single
group were younger (mean 830.49 days) than those in the
combination group (mean 848.83 days). The mean temperature
at first antipyretic administration was 38.63 ℃ in all children
and was higher, at 38.76 ℃, in the combination group and lower,
at 38.59 ℃, in the single group, with statistical significance
(P<.001). The mean maximum temperature in the combination
group was higher than that in the single group (single 38.98 ℃
vs combination 39.29 ℃; P<.001). However, the mean fever
duration was shorter in the single group than in the combination
(single 25.08 hours vs combination 28.81 hours; P<.001).
When cases were divided by the onset temperature, the most
common onset temperatures were between 38 and 39 ℃ in
140,160 cases, followed by those between 39 and 40 ℃ in
51,674 cases. There were 5.49% (11,361/206,859) of cases in
whom antipyretics were administered under 38 ℃. In particular,
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0.18% (377/206,859) of cases used antipyretics under 37 ℃
(Table 1). The use of combination antipyretics increased with
temperature: 23.81% (33,379/140,160) used a combination
when the temperature was between 38 and 39 ℃, while 41.40%
(1517/3664) used a combination when the temperature was >40
℃. In contrast, use of single antipyretics decreased from 76.19%
(106,781/140,160) to 58.60% (2147/3664) as the temperature
increased.






104,337 (50.44)0.025<.00128,173 (51.37)76,164 (50.10)Sex, male, n (%)
835.35 (529.80)0.035<.001848.83 (517.23)830.49 (534.18)Age (days), mean (SD)
3,584,748——c1,057,615 (29.50)2,527,133 (70.50)Temperature records, n (%)
1,076,002——369,685 (34.36)706,317 (65.64)Antipyretic records, n (%)
38.63 (0.54)0.31<.00138.76 (0.56)38.59 (0.53)Temperature at first antipyretic,℃ administra-
tion,℃, mean (SD)
39.09 (0.65)0.49<.00139.29 (0.58)38.98 (0.67)Maximum temperature, ℃, mean (SD)
1686 (0.82)0.002.58457 (0.83)1229 (0.81)Diagnosisd (ICD-10 CM code), n (%)
349 (20.70)0.41.16105 (22.98)244 (19.985)Acute upper respiratory infections of multiple
and unspecified sites/acute tonsillitis (J06, J03),
n (%)
291 (17.26)0.38.6876 (16.63)215 (17.49)Acute nasopharyngitis (J00), n (%)
266 (15.77)0.37.8973 (15.98)193 (15.70)Influenza and pneumonia (J09-J11), n (%)
26.02 (17.22)0.22<.00128.81 (16.40)25.08 (17.38)Duration of fever, hours, mean (SD)
Cases according to the onset temperature, n (%)
3770.03<.00149 (13.00)328 (87.00)Temperature < 37 ℃
10,9840.09<.0012079 (18.93)8905 (81.07)37 ℃ ≤ Temperature < 38 ℃
140,1600.19<.00133,379 (23.81)106,781 (76.19)38 ℃ ≤ Temperature < 39 ℃
51,6740.23<.00117,818 (34.48)33,856 (65.52)39 ℃ ≤ Temperature < 40 ℃
36640.09<.0011517 (41.40)2147 (58.60)Temperature ≥ 40 ℃
aStudent t test between the single and combination groups.
bCohen effect size: 0.2, small; 0.5, medium; 0.8, high.
cNot applicable.
dDiagnosis included within 1 week before and after onset of fever. The 3 most frequently registered diagnoses are listed in order of frequency.
Antipyretic Drug Administration Pattern
Within the single group, ACE was the most commonly
administered (60,929/152,017, 40.08%) single agent, followed
by dexibuprofen (DEX) in 36.74% (55,847/152,017) and IBU
in 23.18% (35,241/152,017; Multimedia Appendix 2). Within
the single group, the mean age was lower in children who were
administered ACE than those who were administered IBU or
DEX (ACE: 714.27 days, IBU: 902.99 days, DEX: 911.54 days).
In the combination group, the ACE-DEX combination
comprised more than half of the total (28,065/54,842, 51.17%),
followed by ACE-IBU (22,277/54,842, 40.62%) and IBU-DEX
(3295/54,842, 6.01%). Ingesting three antipyretics
(ACE-IBU-DEX) accounted for 2.20% (1205/54,842).
In the single group, ACE was the most administered drug when
the temperature was between 37 and 38 ℃ in 39.66%
(4356/10,984) of cases and between 38 and 39 ℃ in 30.99%
(43,442/140,160) of cases. DEX was the second most
administered antipyretic agent when the onset temperature was
<40 ℃ but was the most administered when the temperature
was >40 ℃ in 23.36% (856/3664) of cases. In the combination
group, ACE-DEX was the most used combination, regardless
of temperature.
ACE as a single agent was not the preferred choice at higher
temperatures (43,442/140,160, 30.99%, vs 12,188/51,674,
23.59%, vs 750/3664, 20.47%: 38 to 39 ℃ vs 39 to 40 ℃ vs
≥40 ℃); however, IBU-DEX was used at a similar frequency,
regardless of temperature (2032/140,160, 1.45%, vs
1041/51,674, 2.01%, vs 80/3664, 2.18%: 38 to 39 ℃ vs 39 to
40 ℃ vs ≥40 ℃).
Comparison of Efficacy Between Different Patterns of
Antipyretics
For the antipyretic effect of single and combination treatment,
the changes of AUC values, as the indicator for total fever
exposure, were analyzed by groups based on the temperature
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at the first antipyretic administration (>38 ℃ group, >39 ℃
group; Table 2). The results according to antipyretic ingredients
are summarized in Multimedia Appendix 3. The single group
showed significantly higher absolute AUC values than the
combination group. In particular, the difference in the AUC
during the first 6 hours of fever showed the highest effect size
than other times. In the >38 ℃ group, IBU showed the highest
AUC at all times, and ACE-IBU showed the highest AUC except
for the first 6 hours among combinations. Moreover, the AUC
at 12 hours was higher with IBU (–8.00 [SD 5.70] than with
ACE-IBU –6.78 [SD 5.21]). Similarly, in the group >39 ℃,
IBU had the highest AUC value, and ACE-IBU had the highest
value among combinations. Triple combination antipyretics
with ACE + IBU + DEX showed the lowest AUC.
Table 2. Comparison of the area under the curve between administration patterns.






Single, AUCa (SD)Time from the onset of fever
(hours)
Temperature above 38 ℃ at the time of first administration of antipyretic
−3.69 (2.79)0.42<.001−2.86 (2.39)−3.99 (2.87)6 
−4.92 (3.7)0.29<.001−4.15 (3.3)−5.21 (3.79)8 
−6.15 (4.54)0.22<.001−5.41 (4.21)−6.42 (4.62)10 
−7.4 (5.4)0.19<.001−6.64 (5.13)−7.68 (5.47)12 
Temperature above 39 ℃ at the time of first antipyretic
−5.11 (3.14)0.41<.001−4.31 (2.64)−5.54 (3.29)6 
−6.99 (4.13)0.29<.001−6.23 (3.61)−7.4 (4.33)8 
−8.89 (5.07)0.24<.001−8.11 (4.58)−9.31 (5.27)10 
−10.8 6 (6.04)0.22<.001−10 (5.55)−11.33 (6.24)12 
bAUC: area under the curve.
aCohen effect size: 0.2, small; 0.5, medium; 0.8, high.
cStudent t test.
The temperature at which the first antipyretic was ingested was
defined as the baseline temperature, and the mean difference in
temperature for each time over 24 hours was compared between
antipyretic administration patterns (Figure 3). As shown in
Figure 3A, fever reduction was higher in the single group before
6 hours, and there was little difference in delta fever between
the two groups after 6 hours. Comparing the antipyretic agents
in the single group, IBU showed the highest fever reduction
before 6 hours. However, there was no significant overall
difference between agents (Figure 3B). In the combination
group, the IBU-DEX combination showed the largest fever
difference before 4 hours, but the ACE-IBU combination
showed the largest fever difference after 4 hours. After 8 hours,
the fever difference between the single and combination groups
or antipyretic agents became very small.
Figure 3. Average temperature changes according to the antipyretic administration pattern for 24 hours in cases where the temperature at the time of
antipyretic administration was >38 ℃: (A) comparison of the single and combination groups and (B) comparison of the type of antipyretic agent
administered.
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This is the first and largest cohort study concerning the
antipyretic use pattern and antipyretic efficacy between single
and combination antipyretics in children using large-scale
patient-generated health data (PGHD) on fever, antipyretic
agents, and temperature. Most patients used single antipyretics,
the most common of which was single ACE. Patients were more
likely to use a combination of antipyretics at higher
temperatures, and the ACE-DEX combination was the most
used. However, fever reduction within 6 hours was significantly
better in the single group than in the combination group, as
reflected by the AUC analysis. Therefore, a combination of
different antipyretics may not have a significant advantage over
a single antipyretic. An additional contribution of this study is
that we analyzed large-scale real-world PGHD rather than
relying on data from a small, clinical-based group; this study
used data derived from anyone using a mobile phone and not
just from a specific hospital or location, which allowed us to
analyze individual data covering a larger area.
Antipyretics in Use
For fever, ACE is the most prescribed drug, followed by IBU
[23]. Both antipyretic agents inhibit prostaglandin synthetase
in the hypothalamus, and both are proven to reduce fever [24].
DEX is an NSAID and a pharmacologically effective enantiomer
of racemic IBU [25]. DEX can exert identical pharmacological
efficacy with smaller doses instead of racemic IBU, which could
potentially decrease side effects [25]. In several trials, IBU and
DEX showed comparable antipyretic effects and tolerability
[25,26]. ACE and IBU or DEX have different modes of action
and therefore have been used in combination.
The Fever Coach app is useful to observe antipyretic use patterns
in the general pediatric population. In this study, 73.5% of cases
used single antipyretics, and most of them used ACE (29.5%).
DEX was the second most used antipyretic at 27.0%. ACE was
used in younger children and was not frequently administered
at higher temperatures. This use pattern might suggest that
parents thought ACE was safer but less effective in fever
reduction than IBU or DEX. These results also revealed parents’
perceptions of the temperature that required antipyretics. Most
cases were administered antipyretics when temperatures were
above 38.0 ℃; however, 5.5% used antipyretics under 38 ℃.
Previous studies on parents’perceptions of fever and antipyretics
revealed that many parents were unfamiliar with fever standards
[27-29]. In a survey of 105 parents from two emergency rooms
in the United States, 81% of parents defined fever as a
temperature <38 ℃ [27]. Additionally, 89% reported
administering antipyretics to their children even though they
seemed comfortable. A survey of 1032 children who visited
tertiary hospitals in Turkey revealed that one-third of them had
temperatures <37.8 ℃ [29]. These and our results suggest that
parents should be educated that temperature does not determine
the severity of the disease [1] and antipyretics should not be
used to reduce fever but rather to relieve discomfort or pain.
Patterns of Alternating or Combination Antipyretics
In Korea, surveys on the use or combination of antipyretics are
limited [28,30]. Most primary pediatricians recommend
alternatively combined rather than simultaneously combined
regimens due to concerns regarding additive adverse effects
[1,31,32]. Although 4 hours was the most frequent interval in
the previous reports, parents also reported alternating therapy
every 2 hours, 3 hours, 4 hours, and 6 hours, suggesting that
there was no consensus on dosing instructions.
Most cases in the combination group (95%) in our study used
an ACE-based combination. ACE-based antipyretics were used
in younger children more than other combinations, with an
average age of 27.7 months, 28.5 months, and 29.0 months in
the ACE-IBU, ACE-DEX, and ACE-IBU-DEX groups,
respectively, while the average age in the IBU-DEX group was
30.0 months. Because the average age of ACE cases in the single
group was younger than IBU or DEX, the combination pattern
in this study might indicate that most parents used ACE first
then IBU or DEX in some cases. In this case, patients were more
likely to alternatively combine antipyretics at higher
temperatures. The ACE-DEX combination was the most
administered (12.3% of the combination group) when the
temperature was between 38 and 39 ℃, whereas 20.2%
administered ACE-DEX when the temperature was >39 ℃.
This might be a use pattern reflective of the caregiver’s concerns
about fever and the perception that antipyretic combination
therapy might be better than monotherapy to reduce fever.
Effects of Alternating or Combination Antipyretics
Using meta-analysis, IBU was equal or more efficacious in
reducing fever than ACE in both pediatric and adult patients
and showed similar adverse events [33]. However, previous
studies have not uniformly favored combination antipyretics.
An Indian study included 89 children using IBU alone or in
combination with ACE in which ACE-IBU was more effective
than ACE alone, but the effect was <0.5 ℃ [34]. A British study
randomized 123 children who received ACE or IBU or both.
They reported a temperature difference >1 ℃ between all
treatments, but only a 0.35 ℃ difference was found between
ACE-IBU and ACE, and 0.25 ℃ between ACE-IBU and IBU
[35]. There are currently no clinical guidelines that routinely
recommend the combined use of antipyretics and no consistent
evidence that combination therapy results in overall
improvement in clinical outcomes.
Here, the magnitude of fever reduction within 6 hours, 8 hours,
10 hours, and 12 hours after administration of the first
antipyretic agent was significantly better in the single than in
the combination group. Patients were more likely to use
combination antipyretics at higher temperatures. However, no
significant benefit was obtained by adding different antipyretic
agents. This trend was consistently observed, regardless of the
type of antipyretics used.
NSAIDs have a ceiling effect as analgesics in that there exists
a dose beyond which there is no additional effect [36]. Higher
doses do not provide additional pain relief but may increase the
likelihood of side effects. ACE also demonstrates a ceiling effect
in pain relief [37]. However, there is no known ceiling effect
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in anti-inflammatory doses of NSAIDs or ACE [37]. Thus, the
effect of combination antipyretics on fever course remains
inconclusive. Based on our results, it is possible that
combination antipyretics reduce fever more slowly, indicating
more fever exposure during the first several hours administration
of the antipyretic agent.
Adverse Effects of Alternating or Combination
Antipyretics
Safety issues are concerning considering the antipyretic
combination treatment. In randomized trials in adults with knee
pain, drug-related adverse effects were significantly higher in
subjects taking combination drugs compared with those taking
IBU monotherapy (51% and 42%; P=.04) [38]. Moreover, the
incidence of diarrhea and hepatotoxicity was significantly higher
in the combination therapy group. Additionally, occasional side
effects including renal failure [39] and hypothermia were
observed [40]. ACE and IBU may cause acute renal failure
synergistically as a result of ACE oxidative metabolites
accumulating in the renal medulla during renal ischemia, which
can be caused by NSAIDs [41,42].
Limitations
Regarding the limitations of this study, the dataset did not
contain information related to adverse effects. In addition, it
was difficult to objectively determine the frequency of
hypothermia because there were many cases where the body
temperature was not entered in the app after the body
temperature became normal. However, the concomitant
medications and causes of fever would vary between each
patient. Thus, it was difficult to assess only antipyretic-related
side effects. Although the frequency was very low, there is a
risk of serious side effects.
Here, fever was defined as a temperature >38 ℃, regardless of
the child’s age. Although fever was originally defined using
rectal temperatures, this is not a readily applicable method and
infrared tympanic and axillary thermometers are more
commonly used [43,44]. However, this dataset did not contain
information on the temperature measurement method or site,
and it was difficult to analyze all relevant factors, including age
and biological factors. Second, a single fever case defined in
this study might not be a fever event under the same conditions.
Concomitant medication or other general conditions might affect
the antipyretic process. Third, since the study was based on
patient-generated data, it was dependent on the user entering
the data correctly and consistently, and we were unable to collect
information on adverse effects. As consistent data could not be
collected over time intervals, we used linear interpolation to
obtain the body temperature hourly. Moreover, assuming that
the change in body temperature over time is linear may have
biased the results. Last, there is a possibility of selection bias
depending on who used this app first. This app might have been
used by caregivers who were either more sensitive or more
concerned about fever. Moreover, the combination antipyretics
might be more actively selected because of a previous history
of fever or febrile convulsions in certain patients. Furthermore,
parents with more severely ill children might have a tendency
to use combined antipyretics. These limitations could be partially
overcome through wearing thermometers and live monitoring
equipment in a future study.
Conclusion
Antipyretic combination patterns were analyzed using real-time
PGHD in a large cohort. Approximately 75% of febrile cases
used single antipyretics (mostly ACE), but combination use
became more frequent as the temperature increased. Single
antipyretics showed faster defervescence and reduced the total
exposure to fever by duration and temperature. Multiple
combined antipyretic administrations did not show definite
advantages over single antipyretic use in reducing fever,
regardless of the different antipyretics. Moreover, there were
also inappropriate uses, such as administering antipyretics at
low temperatures or in triple combinations.
Thus, these data suggest that implementation of educational
programs and guidelines regarding the proper management of
a febrile child are needed, and a mobile app could be a useful
platform for this purpose. Single antipyretics are effective in
relieving discomfort in febrile children. Combination
antipyretics may place children at an increased risk without
additional benefit. When educating caregivers, health care
providers should minimize fever phobia and emphasize the
importance of monitoring the signs and symptoms of a child
and improving the child’s comfort in addition to the appropriate
dosing of antipyretics.
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DEX: dexibuprofen
IBU: ibuprofen
NSAID: nonsteroidal anti-inflammatory drug
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